Literature DB >> 28668966

Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.

Hongwei Li1, Xiaoli Yuan2, Dongming Yan1, Dongpeng Li1, Fangxia Guan3, Yang Dong1, Hao Wang1, Xianzhi Liu1, Bo Yang1.   

Abstract

BACKGROUND/AIM: Multidrug resistance (MDR) is largely responsible for the failure of chemotherapy. The long non-coding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript (MALAT1) has been reported to be closely related to tumor biology. In the present study, whether MALAT1 contributes to the resistance of glioblastoma cell lines to temozolomide (TMZ) was investigated.
METHODS: The glioblastoma cell lines U251 and U87 were exposed to increasing concentrations of TMZ to generate TMZ-resistant colonies (the U251/TMZ and U87/TMZ cell lines). The expression levels of MALAT1 and proteins related to epithelial-mesenchymal transition (EMT) were detected by real-time PCR and western blot, respectively. After the transfection of si-MALAT1 or pcDNA-MALAT1, cell viability, mRNA expression of MDR-associated proteins (MDR1, MRP5 and LRP1), and protein expression of EMT related proteins (ZEB1, Snail and SLUG) were evaluated.
RESULTS: The expression of MALAT1 was upregulated in the U251/TMZ and U87/TMZ cell lines compared to that in U251 and U87 cell lines, respectively. The treatment of si-MALAT1 decreased MDR1, MRP5, and LRP1 expression, enhanced cell sensitivity to TMZ, and downregulated ZEB1 protein expression, whereas pcDNA-MALAT1 had the opposite effects. However, the effects of si-MALAT1 on MDR -associated protein expression, cell viability, and EMT status were reversed by the transfection of pcDNA-ZEB1, and the effects of pcDNA-MALAT1 were reversed by the transfection of si-ZEB1. In vivo, MALAT1 overexpression enhanced tumors' TMZ resistance and upregulated ZEB1 expression.
CONCLUSION: MALAT1 decreased the sensitivity of resistant glioma cell lines to TMZ by regulating ZEB1.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Drug resistance; Epithelial-mesenchymal transition; Glioma; MALAT1

Mesh:

Substances:

Year:  2017        PMID: 28668966     DOI: 10.1159/000478917

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  37 in total

1.  Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.

Authors:  David J Voce; Giovanna M Bernal; Longtao Wu; Clayton D Crawley; Wei Zhang; Nassir M Mansour; Kirk E Cahill; Szymon J Szymura; Abhineet Uppal; David R Raleigh; Ruben Spretz; Luis Nunez; Gustavo Larsen; Nikolai N Khodarev; Ralph R Weichselbaum; Bakhtiar Yamini
Journal:  Cancer Res       Date:  2019-04-02       Impact factor: 12.701

2.  Knockdown of long non-coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells.

Authors:  Hanxue Zou; Hongxia Li
Journal:  Exp Ther Med       Date:  2019-09-30       Impact factor: 2.447

3.  TGF-β-activated lncRNA LINC00115 is a critical regulator of glioma stem-like cell tumorigenicity.

Authors:  Jianming Tang; Bo Yu; Yanxin Li; Weiwei Zhang; Angel A Alvarez; Bo Hu; Shi-Yuan Cheng; Haizhong Feng
Journal:  EMBO Rep       Date:  2019-10-10       Impact factor: 8.807

Review 4.  The association of long non-coding RNA in the prognosis of oral squamous cell carcinoma.

Authors:  Agnik Haldar; Ajay Kumar Singh
Journal:  Genes Genomics       Date:  2022-01-13       Impact factor: 1.839

5.  Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition.

Authors:  Jianjiao Wang; Fenggang Zhou; Yang Li; Qingsong Li; Zhichao Wu; Lili Yu; Fei Yuan; Jie Liu; Yu Tian; Yu Cao; Yan Zhao; Yongri Zheng
Journal:  Cell Cycle       Date:  2017-12-10       Impact factor: 4.534

6.  Lantern: an integrative repository of functional annotations for lncRNAs in the human genome.

Authors:  Swapna Vidhur Daulatabad; Rajneesh Srivastava; Sarath Chandra Janga
Journal:  BMC Bioinformatics       Date:  2021-05-26       Impact factor: 3.169

Review 7.  The Dark Side of the Epitranscriptome: Chemical Modifications in Long Non-Coding RNAs.

Authors:  Roland Jacob; Sindy Zander; Tony Gutschner
Journal:  Int J Mol Sci       Date:  2017-11-10       Impact factor: 5.923

8.  Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.

Authors:  Sang-Soo Kim; Joe B Harford; Manish Moghe; Antonina Rait; Kathleen F Pirollo; Esther H Chang
Journal:  Nucleic Acids Res       Date:  2018-02-16       Impact factor: 16.971

Review 9.  Role of Long Non-Coding RNAs in Conferring Resistance in Tumors of the Nervous System.

Authors:  Soudeh Ghafouri-Fard; Amin Agabalazadeh; Atefe Abak; Hamed Shoorei; Mohammad Mehdi Hassanzadeh Taheri; Mohammad Taheri; Guive Sharifi
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

Review 10.  Exosomal noncoding RNAs: key players in glioblastoma drug resistance.

Authors:  Ahmad Movahedpour; Seyyed Hossein Khatami; Marjan Khorsand; Mahsa Salehi; Amir Savardashtaki; Seyedeh Habibeh Mirmajidi; Babak Negahdari; Nezhat Khanjani; Parisa Naeli; Omid Vakili; Mortaza Taheri-Anganeh
Journal:  Mol Cell Biochem       Date:  2021-07-17       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.